Previous 10 | Next 10 |
Epizyme (EPZM): Q1 GAAP EPS of -$0.69 misses by $0.12.Revenue of $7.63M (+465.2% Y/Y) beats by $0.76M.2021 Financial GuidanceBased on its current operating plans, Epizyme expects its current cash runway to extend into 2023. Additionally, the Company expects its non-GAAP adjusted operating exp...
Total Revenue of $7.6 Million for 1Q 2021; TAZVERIK ® Net Product Revenues of $6.2 Million Ongoing TAZVERIK Clinical Trials in both Follicular Lymphoma and Prostate Cancer Demonstrate Encouraging Preliminary Safety and Activity Data Investigational New Drug (I...
Epizyme (NASDAQ:EPZM) is scheduled to announce Q1 earnings results on Thursday, May 6th, before market open.The consensus EPS Estimate is -$0.56 (-9.8% Y/Y) and the consensus Revenue Estimate is $6.66M (+393.3% Y/Y).Over the last 1 year, EPZM has beaten EPS estimates 75% of the time and has b...
Epizyme , (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call and webcast to discuss its first quarter 2021 financial results and provide a bu...
Epizyme Inc. (NASDAQ:EPZM) traded today at a new 52-week low of $7.37. This new low was reached on below average trading volume as 220,000 shares traded hands, while the average 30-day volume is approximately 1.4 million shares. Epizyme Inc is a clinical-stage biopharmaceutical company t...
Epizyme is at a multi-year low. Main cause of disappointment is slow sales of Tazverik. Potential is great with label expansion and epigenetic pipeline. For further details see: Epizyme Comeback Is Likely, Price Makes It A Buy
Can-Fite BioPharma Ltd. (CANF) +87% on out-licensing psoriasis, liver disease drug rights.SunLink Health Systems, Inc. (SSY) +55% on announcing $2 Million expansion, capital and operating improvements at Trace Regional Hospital.Annovis Bio, Inc. (ANVS) +37% as ANVS401 improves ...
The following slide deck was published by Epizyme, Inc. in conjunction with this event. For further details see: Epizyme (EPZM) Presents At The Next EPIsode: Rewriting Oncology Treatment with Epigenetics - Slideshow
The following slide deck was published by Epizyme, Inc. in conjunction with this event. For further details see: Epizyme (EPZM) Presents At Barclays Global Healthcare Conference - Slideshow
Epizyme’s Next EPIsode: Vision for Rewriting Oncology Treatment with Epigenetics Showcased New Five-Year Corporate Strategy Preliminary Safety and Activity Data from Ongoing Clinical Trials for TAZVERIK ® Combinations in Follicular Lymphoma and Prostate Cancer ...
News, Short Squeeze, Breakout and More Instantly...
TAZVERIK® (tazemetostat) Net Product Revenue of $11.0 Million for 2Q 2022; Total End User Demand Grew 17% vs. 1Q 2022 First Patient Dosed in the SET-101 Phase 1/1b Study of EZM0414, the Company’s Novel, First-in-Class, Oral SETD2 Inhibitor Merger with I...
The biotech investment sector has always been its own market, very distinct from other sectors. So it was no surprise that when most sectors turned slowly upward after the pandemic-inspired crash, Biotech (XBI) rose 164%, exceeding the overall market (SPY) performance by triple digits. Then, a...
Shares of the commercial-stage cancer company Epizyme (NASDAQ: EPZM) are soaring today. Specifically, the drugmaker's stock is up by a handsome 58% as of 10:50 a.m. ET Monday. Epizyme's shares are racing higher today in response to a buyout agreement with French biopharma Ipse...